Page 12 - Global External News Today

In the Phase IIb NATIVE, lanifibranor met both the primary and key secondary endpoints, including NASH resolution with no worsening of fibrosis and improvement of liver fibrosis with no worsening of NASHNATIVE

Investegate announcements from INVENTIVA, Inventiva announces the presentation of five scientific abstracts at the AASLD The Liver Meeting™ 2021

Inventiva announces the implementation of an At-The-Market program in the United States Daix (France), August 2, 2021 (GLOBE NEWSWIRE) – Inventiva S.A. (NASDAQ: IVA – EURONEXT PARIS: IVA) (the “ Company”), a clinical-stage biotechnological company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical need in the areas of fibrosis, lysosomal storage disorders and oncology, today announced the implementation of an At-The-M...

INVENTIVA: Inventiva announces three scientific presentations at the EASL International Liver Congress 2021 and during a KOL webcast event the beneficial effects of lanifibranor on cardiovascular risk biomarkers in patients with NASH the positive effects of lanifibranor on several biomarkers of disease activity and associated risks in patients with NASH and F2/F3 fibrosis One poster presentation showing the beneficial effects of the combination treatment of lanifibranor and ACC1/2 inhibitor fir...

Important Notice This press release contains forward-looking statements, forecasts and estimates with respect to Inventiva’s clinical trials, clinical trial data releases, clinical development plans and anticipated future activities of Inventiva. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” ...

INDIANAPOLIS--(BUSINESS WIRE)--Jun 1, 2021--

The Global External AC-DC Power Market Research Report 2021-2026, offers an in-depth evaluation of each crucial aspect of the Global External AC-DC Po

About Inventiva  Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of NASH, MPS and other diseases with significant unmet medical need. Leveraging its expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation, Inventiva is currently advancing two clinical candidates, as well as a deep pipeline of earlier stage programs. Lanifibranor, its lea...

INVENTIVA: Inventiva to participate at the Jefferies Virtual Healthcare Conference Daix (France), May 25, 2021 - Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced that the Company will participate to the upcoming Jefferies Virtual Healthcare ...

The External AC-DC Power Consumption market outlook looks extremely promising is a valuable source of insightful data for business strategists. It pro